European Commission Grants Orphan Drug Designation For aTyr Pharma's Efzofitimod For Treatment Of Systemic Sclerosis
Portfolio Pulse from Bill Haddad
The European Commission has granted Orphan Drug Designation to aTyr Pharma's Efzofitimod for the treatment of systemic sclerosis. This designation provides regulatory and financial incentives for the development of the drug.
June 22, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
aTyr Pharma's Efzofitimod receives Orphan Drug Designation from the European Commission for the treatment of systemic sclerosis, providing regulatory and financial incentives for the drug's development.
The Orphan Drug Designation granted by the European Commission directly benefits aTyr Pharma (LIFE) by providing regulatory and financial incentives for the development of Efzofitimod. This positive news is likely to have a short-term positive impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100